Nine characteristics shared by the most successful mAb

February 1, 2019News, Therapeutic Antibody R&Dantibody discovery, monoclonal antibody drug, therapeutic antibodybiorab

The path to finding a therapeutic antibody that leads to significant medical improvements is often complicated, long, and costly. Many criteria have to be taken into account in order to begin theRead More…

Sixteen New Tumor Drugs First Approved in 2018

December 28, 2018News, Therapeutic Antibody R&Dantibody discovery, therapeutic antibodybiorab

In 2018, from the approval of JNJ’s apalutamide in the United States on February 14 to that of larotrectinib on November 26, a total of 16 new tumor drugs were approved forRead More…

Nat Genet：Scientists Discover New Target for Immunotherapy Following 2018 Nobel Prize for Medicine

December 20, 2018News, Therapeutic Antibody R&Dantibody discovery, immunotherapy, monoclonal antibody drug, therapeutic antibodybiorab

Following the 2018 Nobel Prize for Medicine, global attention is now more than ever turned toward the promise of immunotherapy in oncology. According to a recent study published in the international journalRead More…

The First Rituxan Biosimilar Is Expected to Be Approved by FDA

October 25, 2018News, Therapeutic Antibody R&Dantibody discovery, monoclonal antibody drug, Rituximab, therapeutic antibodybiorab

B cell lymphoma is a solid tumor that occurs in B cells, including Hodgkin’s lymphoma and non-Hodgkin’s lymphoma. In numerous types of B cell lymphoma, classic Hodgkin’s lymphoma and nodular lymphocyte areRead More…

First Approval for Fremanezumab-vfrm

September 27, 2018News, Therapeutic Antibody R&Dantibody discovery, monoclonal antibody, monoclonal antibody drug, therapeutic antibodybiorab

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved AJOVYTM (fremanezumab-vfrm) injection for the preventive treatment of migraine in adults. AJOVY, aRead More…

Antibody Combo Knocks Down HIV in Clinical Trials

September 27, 2018News, Therapeutic Antibody R&Dantibody combination, blocking antibody, hiv immunology, monoclonal antibody, monoclonal antibody drug, therapeutic antibodybiorab

A mix of two monoclonal antibodies against HIV tamped down virus levels in patients not taking antiretroviral medication, according to the results of two early-stage clinical trials reported in nature. After several infusionsRead More…

Cancer Dis: Scientists Reveal New Mechanisms of Drug Resistance in Cancer Immunotherapy

August 3, 2018News, Therapeutic Antibody R&Dimmnunocheckpoint, Immune checkpoint therapy, monoclonal antibody drug, PD-1, pd-L1, therapeutic antibodybiorab

It is well known that the immune system can recognize and remove cancerous cells under normal conditions, but tumor cells will inhibit the immune system in the tumor development process, through differentRead More…

Genetech’s New Drug Rituxan Approved for the Treatment of Serious Immune Diseases as a New Breakthrough during 60 Years

July 5, 2018News, Therapeutic Antibody R&Dimmune disesase, monoclonal antibody drug, pemphigus vulgaris, Rituximab, therapeutic antibodybiorab

A few days ago, Genentech, a Roche Group member, announced that the US FDA approved Rituxan® (rituximab) for the treatment of moderate to severe pemphigus vulgaris (PV). It is worth mentioning thatRead More…

The World’s First Single-domain Antibody Drug Cablivi Is on The Market

June 29, 2018News, Therapeutic Antibody R&Dacquired thrombocytopenic purpura, Cablivi, caplacizumab, Single-domain Antibodybiorab

Recently the European Medicines Agency (EMA) Committee on Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of Cablivi (caplacizumab), a single-domain antibody (sdAb) drug developed byRead More…

Scientists Found Key Factors Determining Anticancer Efficacy of Immune Checkpoint Therapy

June 29, 2018News, Therapeutic Antibody R&DFLT3LG, Immune checkpoint therapy, key factors, natural killer NK cell, PD-1, stimulating dendritic cellbiorab

Intratumoral stimulating dendritic cells (SDCs) play a key role in stimulating cytotoxic T lymphocytes and promoting immune responses against cancer. The study of mechanisms regulating the enrichment of SDCs in tumor microenvironmentRead More…